Preclinical studies showed that adoptive transfer of LAK cells into tumor-bearing mice resulted in anti-tumor activity, and the concomitant administration of IL-2 with LAK cells increased in vivo anti-tumor activity of LAK cells (4, 63–65). The gene discussed is IL2; the disease is neoplasm.